GlassScriptPhysician profile
Jaime Zeledon
NPI 1043666092
$3,031.70
in general payments reported to CMS, 2019-2025
11 companies · $85.02 in 2025
The $85.02 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $2,077 · 2023: $391 · 2024: $349 · 2025: $85.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,906.46 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $263.37 | 2021-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $193.69 | 2021-2024 | Belbuca |
| Hikma Pharmaceuticals USA | $156.92 | 2021-2022 | |
| Painteq LLC | $143.94 | 2023-2024 | Painteq |
| Valinor Pharma, LLC | $121.98 | 2024-2025 | Movantik |
| Abbvie INC. | $111.39 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $73.36 | 2021 | |
| Si-Bone, INC. | $21.45 | 2022 | |
| Curonix LLC | $19.93 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Allergan, INC. | $19.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Zeledon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.